Rhinocort is a nasal spray containing the active ingredient budesonide. It is also known by the name Rhinocort Aqua. This medication is used to treat nasal allergy symptoms such as congestion, sneezing, and runny nose.
The common price range for Rhinocort lies between £26.35 – £63.92 per inhalers. This range is subject to the size of the packaging and the potency of the contained ingredients (1 or 10 mcg).
Rhinocort is a corticosteroid used to manage and alleviate symptoms of nasal allergies. It reduces inflammation and is effective for treating allergic rhinitis.
The active ingredient in Rhinocort is Budesonide. Budesonide is known for its potent anti-inflammatory properties and its ability to reduce symptoms of nasal congestion, sneezing, and runny nose.
Rhinocort is available as a nasal spray. Each bottle typically provides a specific number of metered doses, ensuring consistent delivery of the medication.
Rhinocort is primarily indicated for the treatment of seasonal and perennial allergic rhinitis. It helps in managing nasal symptoms such as itching, congestion, and sneezing.
The usual recommended dose for adults and children over six years is one spray in each nostril once daily. For maintenance, the dosage may be adjusted to the lowest effective dose.
Shake the bottle well before use. Prime the spray if using it for the first time or after a period of non-use. Insert the nozzle into a nostril, close the other nostril, and spray while gently inhaling through the nose.
Store Rhinocort at room temperature, away from direct sunlight and moisture. Ensure the cap is tightly closed when not in use. Keep out of reach of children.
Budesonide, the active ingredient, works by inhibiting the release of inflammatory mediators from cells. This action significantly reduces the inflammatory response in nasal tissues, leading to symptom relief.
After nasal administration, Budesonide exhibits rapid absorption. The drug has a high first-pass metabolism in the liver, resulting in systemic bioavailability of approximately 33%. Its primary route of excretion is via the urine and feces.
Rhinocort is contraindicated in individuals with known hypersensitivity to Budesonide or any of the excipients contained in the formulation. It should not be used in patients with untreated localized infections involving the nasal mucosa.
Budesonide is metabolized by the enzyme CYP3A4. Concurrent use of strong CYP3A4 inhibitors, such as ketoconazole, may increase systemic exposure to Budesonide and potentially enhance adverse effects.
Common side effects include nasal irritation, headache, and sore throat. Rare but serious side effects might involve nosebleeds and ulcerations in the nasal tissue.
Patients using Rhinocort for extended periods should have their growth monitored, especially in children. Periodic assessment of nasal mucosa is advisable to detect any signs of local adverse effects.
If a dose is missed, administer it as soon as possible. If it is nearly time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose.
In the event of an overdose, symptomatic and supportive treatment is recommended. Due to the low systemic bioavailability of Rhinocort, an overdose is unlikely to cause life-threatening complications.
When using Rhinocort for the first time, prime the spray by releasing five actuations into the air, away from your face. This ensures that the pump delivers the correct dose.
The container and spray mechanism of Rhinocort are designed to minimize contamination. The unique formulation maintains sterility throughout its shelf life.
Caution is advised when prescribing Rhinocort to patients with moderate to severe hepatic impairment as Budesonide metabolism may be affected, leading to increased systemic exposure.
Rhinocort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Budesonide is excreted in human milk; thus, caution should be exercised when administered to nursing mothers.
Budesonide acts on glucocorticoid receptors, promoting anti-inflammatory gene expression which reduces the release of inflammatory cytokines and other mediators from nasal epithelial cells.
Clinical trials have demonstrated Rhinocort’s efficacy in reducing nasal symptom scores in patients with allergic rhinitis. The onset of action is generally within hours, with significant improvement observed within a week of consistent use.